NanoSyrinx.

Nanosyringes – a novel high-precision drug delivery system.

NanoSyrinx is discovery-stage synthetic biology company focused on the development of nanosyringes which inject bioactive proteins and peptides through cell membranes for precision intracellular targeting. 

Technology & Products.

NanoSyrinx’s technology is built upon a fully customizable, proprietary genetic platform that has been incorporated into industry-scalable expression systems. The platform produces a novel class of protein nanosyringes which deliver bioactive peptide and protein payloads directly to the interiors of targeted cells. The platform has been validated with a range of payloads including short peptides and complex enzymes.

The Market.

Current estimates are that <20% of know human proteins have been drugged and the vast majority of these are on the cell surface or circulating outside of the human cell. There is a vast untapped market opportunity to deliver the latest generation of biologic drugs (e.g. antibodies, nanobodies and gene editing therapies) to targets inside the cell. Market demand has been validated through extensive customer discovery during the ICURe programme and a bespoke market report delivered by IP Pragmatics under the BBSRC Pathfinder Scheme. The market opportunity for nanotechnology-enabled drug delivery is estimated to be $136bn by 2021, growing at 12.5%.

Business Model.

NanoSyrinx will operate a hybrid business model, delivering both in house and partnered programmes aimed at developing the next generation of precision medicines to address areas of unmet medical need. 

Fundraising to date.

Innovate UK UKI2S Accelerator grant £200k
Further seed funding from:
M Ventures, BioCity Investment Fund, UKI2S Seed Fund
The company is currently raising  £4m.

Team.

Chairman: Steve Taylor

CEO & Co-founder:  Dr Joe Healey

Scientific Advisor & Co-founder: Prof. Nick Waterfield

Business Advisor: Dr James Lapworth

Contact: j.lapworth@warwick.ac.uk  | https://www.nanosyrinx.com

KEY FEATURES.

9C12A659-F601-4D82-B0B7-58B26B8FB50E

Office space

In oculis quidem se esse vult, summumque malum et, quantum.

Lab space

In oculis quidem se esse vult, summumque malum et, quantum.

Business support

In oculis quidem se esse vult, summumque malum et, quantum.

8BA7CC87-ADB9-4E9E-B6B0-0F609EA2D3A9

Meeting rooms

In oculis quidem se esse vult, summumque malum et, quantum.

Virtual tenancy

In oculis quidem se esse vult, summumque malum et, quantum.

Hot desks

In oculis quidem se esse vult, summumque malum et, quantum.

IP Status

In oculis quidem se esse vult, summumque malum et, quantum.

Opportunity

In oculis quidem se esse vult, summumque malum et, quantum.

Application areas

In oculis quidem se esse vult, summumque malum et, quantum.

Management Team

In oculis quidem se esse vult, summumque malum et, quantum.

27D4EAE4-6FBF-4578-BCBD-4F102E515086

Investment Stage

In oculis quidem se esse vult, summumque malum et, quantum.

1EEFF807-B5A2-4190-89BC-DE59BFF00B15

Investors

In oculis quidem se esse vult, summumque malum et, quantum.

Technology Readiness

In oculis quidem se esse vult, summumque malum et, quantum.

Make An Enquiry.